Immune cell therapy takes on IBD: a new hope for tough cases?
NCT ID NCT07309744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in 30 adults with moderate-to-severe ulcerative colitis or Crohn's disease who haven't responded to standard treatments. The therapy targets specific immune cells to reduce inflammation in the gut. The main goal is to check safety and find the best dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE (CD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong Univerdity of Science and Technology
Wuhan, Hubei, 430022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can upadacitinib sustain remission in Crohn's disease?
- Can a new pill tame ulcerative colitis?
- Could a new injection tame ulcerative colitis?
- Ultrasound may help surgeons remove the right amount of bowel in Crohn's disease
- Can a special diet calm Crohn's Flare-Ups?
- New study explores simple tests to replace colonoscopies for colitis patients